A Circular Debate
Are continuous manufacturing technologies proving their worth in practice?
Maryam Mahdi | | Longer Read
This article was published in our sister publication, The Small Molecule Manufacturer, which celebrates the field of small molecule drug development and manufacturing with interviews and articles focusing on success stories, equipment, and new processing techniques. Read more about The Small Molecule Manufacturer here https://themedicinemaker.com/manufacture/small-but-never-forgotten
Given the oft-discussed advantages of continuous manufacturing in meeting pharma’s demands for rapid development, reduced costs, and increased manufacturing flexibility, why does batch manufacturing still dominate the market? And does 2020 mark the start of the continuous revolution?
Bringing together professionals from across the pharmaceutical industry, IMA Active’s ”Can’t Stop the Future” event provided an opportunity to discuss the practical hurdles involved in the adoption of continuous manufacturing and how the regulatory landscape is evolving to help support companies ready to take the leap. According to Guia Bertuzzi, Product Manager at IMA SpA, the large turnout was indicative of the growing interest in continuous manufacturing. And with over 200 attendees with varied interests, there was much to be discussed.
Read the full article now
Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.